In:
Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 37, No. 15_suppl ( 2019-05-20), p. e14606-e14606
Abstract:
e14606 Background: Hematological malignancies are forms of cancer that originate in blood-forming tissue, such as bone marrow, or in the cells of the immune system. Hematological malignancies can be classified as leukemias, lymphomas, multiple myeloma (MM), myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) based on the cell type where they originate. Detection of genetic alteration in hematological malignancies is increasingly important because of diverse variants associated with classification and diagnosis of subtypes, and prognostic and therapeutic-response prediction. Next-generation sequencing (NGS) is an advanced technology to simultaneously analyze multiple genes to identify clinically well-described variants, as well as rare variants related for clinical diagnostics. Methods: We developed the targeted NGS panel, HEMEaccuTest and automatic analysis software, NGeneAnalySys for estimating the relative pathogenicity of hematological malignancies. HEMEaccuTest covers about the 310 kilobases with exon regions of 108 genes that have putatively known for associations with the diseases according to the WHO, NCCN and ELN guidelines. the diagnostic utility of the panel and software were validated using genotype-known reference materials and clinical specimens. Results: The results showed that pathogenic variants were effectively detected with an average coverage depth of 600x and a minimum coverage depth of 100x. It demonstrated an excellent limit of detection, with 100% sensitivity for SNVs at 2% VAF and for indel at 4% VAF. In addition, the analytical sensitivity and specificity of the panel were high in a comparison to conventional methods such as Sanger sequencing, FISH, and real-time PCR. Noticeably, the approximately 300-bp-size insertions of FLT3-ITD was efficiently detected by an excellent simulating algorithm of NGeneAnalySys. Conclusions: This analytical validation demonstrated that HEMEaccuTest and NGeneAnalySys can be an excellent tool for disease definition and therapeutic strategy in hematological malignancies.
Type of Medium:
Online Resource
ISSN:
0732-183X
,
1527-7755
DOI:
10.1200/JCO.2019.37.15_suppl.e14606
Language:
English
Publisher:
American Society of Clinical Oncology (ASCO)
Publication Date:
2019
detail.hit.zdb_id:
2005181-5
Permalink